Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07483450 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

StatusActive, Not Recruiting
PhasePhase 4
Started2025-07-04
View on ClinicalTrials.gov ↗
The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).

Amendment history 3 changes detected by DataLookout

2026-07-07
Trial status changed: Recruiting → Active, Not Recruiting
2026-07-07
Primary completion pushed: 2027-03-12 → 2027-12-31
2026-07-07
Completion pushed: 2027-04-23 → 2028-12-31
Trial Details
NCT Number NCT07483450
Lead Sponsor Hoffmann-La Roche
Conditions Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Enrollment 60 participants
Start Date 2025-07-04
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-06